IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report

IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report

Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small cell lung cancer. The unique adverse events that can arise after treatment with ICIs are known as immune-related adverse events (irAE). As the number of cases under treatment with ICIs increases, new typ...

Full description

Bibliographic Details
Main Authors: Takeshi Terashima, Eri Iwami, Takashi Shimada, Aoi Kuroda, Tatsu Matsuzaki, Takahiro Nakajima, Aya Sasaki, Keisuke Eguchi
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Pulmonary Medicine
Subjects:
Durvalumab
IgG4-related pleural disease
Immune checkpoint inhibitors
Immune-related adverse events
Lung cancer
Online Access:http://link.springer.com/article/10.1186/s12890-020-1150-x

Internet

http://link.springer.com/article/10.1186/s12890-020-1150-x

Similar Items